I have finalised the demo for the ICH-GCP E6 R3 refresher course. Overall, I liked the content and the interface. I also want to thank Whitehall Train...
About
Post-Approval Variations and Lifecycle Maintenance training provides comprehensive knowledge of managing regulatory changes to approved pharmaceutical products. The course covers variation classification, Type IA, Type IB and Type II procedures, extensions, grouping, super-grouping, worksharing, submission requirements, assessment timelines, implementation and notification obligations.
This Post-Approval Variations and Lifecycle Maintenance Training Course provides practical understanding of applying EU and UK variation requirements, including Regulation (EC) No 1234/2008, Delegated Regulation (EU) 2024/1701, current variations guidance and applicable MHRA requirements. The course supports professionals in selecting the correct regulatory pathway, planning submissions, managing regulatory timelines, maintaining documentation and implementing effective lifecycle strategies for marketing authorisations.
- Regulatory Affairs Professionals
- Regulatory Intelligence Professionals
- Quality Assurance and Quality Control Professionals
- Pharmaceutical Manufacturing and Technical Operations Teams
- Pharmacovigilance Professionals
- Supply Chain and Product Lifecycle Teams
- Marketing Authorisation and Lifecycle Management Specialists
- Anyone involved in managing post-approval changes and regulatory maintenance of pharmaceutical products
What you will learn
Understand the fundamentals of post-approval variations and lifecycle maintenance, including variation classification, regulatory scope, extensions, and the principles governing changes to approved marketing authorisations.
Learn the regulatory requirements for Type IA, Type IB and Type II variations, including classification criteria, submission requirements, timelines, implementation, notification and assessment procedures under applicable EU and UK frameworks.
Gain practical knowledge of grouping, super-grouping, worksharing, unforeseen variations, urgent safety changes and lifecycle strategies, including how to select the appropriate regulatory pathway for complex post-approval changes.
Understand how to effectively manage post-approval lifecycle activities, including regulatory planning, submission tracking, annual reporting, change implementation, documentation, commitments, and ongoing maintenance of compliant marketing authorisations.
Course Syllabus
- Two instruments moved, and the desk aid missed both
- The words this subject uses in its own way
- Inside the Annex: how an entry is built and how to check one
- Annexes I to VI, by subject
- Variation or extension - and why the difference is a route
- How this framework actually evolves
- The package that is not law, and the method that survives it
- What actually makes a change a type IA
- Do and tell, and the date that starts everything
- Twelve months, counted from the oldest
- The cycle that restarted on 15 January 2026
- IA-IN: the entry decides, not you
- Grouped, super-grouped, or in a mixed group
- Thirty days, and what a non-acceptance costs
- Type IB is what is left over
- The default is not final, and one clock conflicts
- Article 9(2): thirty days, and where day zero is
- The unfavourable opinion and the day-ninety boundary
- Type II: sixty days, ninety, and sometimes thirty
- Clock stops, post-opinion periods, re-examination
- Article 22: twenty-four hours and fifteen days
- Four words, four legal bases
- Grouping under Article 7 and Annex III
- Article 7a super-grouping
- Article 6a additional regulatory tools
- Article 20 worksharing
- The MHRA's October 2025 grouping guidance
- Making a group defensible
- The MHRA aligned. It did not diverge.
- Regulation 65C is a doorway. Schedule 10A is the room.
- Four descriptors, and a prefix that is not a territory
- Where a United Kingdom authorisation can and cannot go
- Recognition, bulk, and the two channels the EU does not have
- Where you file, where you watch, and what you must not remember
- Renewals: five years, and then an unlimited period
- Restated at the close: what changed, and what did not
- The dated positions this course rests on, and how each is graded
- The European decisions, in the order they are actually taken
- Then run it again: the United Kingdom decisions, in order
- What this course did not claim, and why it did not
- The six items most likely to have moved since verification
- Five Things to Take From This Course
- What to do when you get back to your own portfolio
- 📘 Bonus:Post-Approval Variations and Lifecycle Maintenance eBook (Free with purchase)
Course Benefits

Get our exclusive eBook with every purchase — a practical companion guide covering post-approval variations, regulatory classification, submission pathways and lifecycle maintenance, yours to keep forever
Gain Continuing Professional Development (CPD) Points, accredited by The Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. These can be used to count towards the distance learning element of any scheme that comes under the umbrella of The Academy of Medical Royal Colleges or any other scheme for which there is mutual recognition.
Receive a personal certificate to show your subject knowledge on course completion.
You get excellent value through our cost-effective prices. We can also offer you group discounts on larger purchases.
The course saves you time through the convenience of online availability. This lets you complete the interactive course at your own comfort.
You will stay up to date with changes to the FATF standards and lists, UK POCA and the Money Laundering Regulations, the EU AML package and AMLA, and US requirements, as our training courses are constantly monitored, reviewed and updated.
The course reflects current financial-crime practice for life-sciences organisations, so learners can apply proportionate, risk-based controls in their own organisation.






